Avid Bioservices (NASDAQ: CDMO) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare Avid Bioservices to related businesses based on the strength of its risk, dividends, institutional ownership, analyst recommendations, earnings, valuation and profitability.
Insider and Institutional Ownership
18.1% of Avid Bioservices shares are held by institutional investors. Comparatively, 43.1% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 2.5% of Avid Bioservices shares are held by insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Avid Bioservices and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Avid Bioservices Competitors||172||843||1854||61||2.62|
Avid Bioservices presently has a consensus price target of $10.00, suggesting a potential upside of 207.69%. As a group, “Biopharmaceuticals” companies have a potential upside of 3.85%. Given Avid Bioservices’ stronger consensus rating and higher probable upside, equities analysts plainly believe Avid Bioservices is more favorable than its competitors.
Valuation & Earnings
This table compares Avid Bioservices and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Avid Bioservices||$57.63 million||-$28.15 million||-4.01|
|Avid Bioservices Competitors||$631.32 million||$62.30 million||74.89|
Avid Bioservices’ competitors have higher revenue and earnings than Avid Bioservices. Avid Bioservices is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Avid Bioservices and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Avid Bioservices Competitors||-13,490.39%||-54.63%||-24.86%|
Volatility & Risk
Avid Bioservices has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500. Comparatively, Avid Bioservices’ competitors have a beta of 1.11, suggesting that their average share price is 11% more volatile than the S&P 500.
Avid Bioservices beats its competitors on 7 of the 12 factors compared.
Avid Bioservices Company Profile
Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides a variety of process development activities, including cell line development and optimization.
Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.